PPIs increase fracture risk

Patients with heartburn, GERD, peptic ulcers or other conditions who take proton pump inhibitors to relieve symptoms are at increased risk of fractures, according to a large new study of patients aged 50 an older.

The study says the risk is for osteoporosis-related fractures, specifically for hip fractures. The risk for hip fractures shows up after 5 years of continuous use, but after 7 years, the risk of all fracture types goes up. The study did not show any correlation between fracture risk and short-term exposure to the medication class. 

The findings are significant because most patients use these medications for the long haul, often indefinitely. The study looked at patients who had hip, spine or wrist fractures and included a control group with no history of any fractures in these areas. 

- read the story at PharmaLive
- review the Canadian Medical Association Journal study
- see a study commentary in CMAJ

Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.